AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

Funding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis MENLO PARK, Calif. –(BUSINESS WIRE)–Sep. 28, 2026– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and